Neurocrine Biosciences CRO Acquires Shares via PRSU Vesting with Tax Withholding

Executive Summary

On September 15, 2026, Neurocrine Biosciences, Inc. ($NBIX) filed a Form 4 on behalf of Chief Regulatory Officer Ingrid Delaet. The filing details the acquisition of 4,483 shares of common stock upon the certification and vesting of performance restricted stock units (PRSUs) on September 11, 2026, alongside the withholding of 2,419 shares to cover associated tax liabilities.

Key Transaction Details

• PRSU Vesting (Code A): 4,483 shares were acquired at an effective price of $0.00 following the certification of performance metrics.
• Tax Withholding (Code F): 2,419 shares were withheld by the issuer at $156.22 per share (totaling $377,896.18) to satisfy statutory tax obligations.
• Net Position Change: Direct ownership increased by a net 2,064 shares, bringing total direct holdings to 18,289 shares.

Insider Context & Market Implications

This transaction was entirely administrative, resulting from PRSU milestone certification and routine tax withholding. Because no discretionary open-market buying or selling occurred, it carries Low trading significance for investors.